Literature DB >> 20347112

Adenovirus 5 and chimeric adenovirus 5/F35 employ distinct B-lymphocyte intracellular trafficking routes that are independent of their cognate cell surface receptor.

Mathieu Drouin1, Marie-Pierre Cayer, Daniel Jung.   

Abstract

Gene transfer applications with adenovirus (Ad) type 5 are limited by its native tropism, hampering their use in several cell types. To address this limitation, several Ad vectors bearing chimeric fiber have been produced to take advantage of the different cellular receptors used by other subgroups of Ads. In this study, we have compared the transduction efficiency of Ad5 and the chimeric Ad5/F35 in primary human B lymphocytes and B-cell lines as a function of the developmental stage. We found that transduction efficiencies of the two Ads differ independently of their targeted cellular receptor but are related to the intracellular localization of the virus. In efficiently transduced cells, Ads were localized in early endosomes or cytosol, whereas in poorly transduced cells they were localized within late endosomes/lysosomes. Finally, we demonstrate that treatment of cells with phosphatase inhibitors known to redirect endocytosis towards caveolae, increased Ad5/F35 transduction efficiency. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347112     DOI: 10.1016/j.virol.2010.03.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

Review 1.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

2.  Overexpression of PAX5 induces apoptosis in multiple myeloma cells.

Authors:  Maryse Proulx; Marie-Pierre Cayer; Mathieu Drouin; André Laroche; Daniel Jung
Journal:  Int J Hematol       Date:  2010-09-30       Impact factor: 2.490

3.  Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes.

Authors:  James S Findlay; Graham P Cook; G Eric Blair
Journal:  Viruses       Date:  2018-01-03       Impact factor: 5.048

4.  Enhanced transduction of CAR-negative cells by protein IX-gene deleted adenovirus 5 vectors.

Authors:  Jeroen de Vrij; Sanne K van den Hengel; Taco G Uil; Danijela Koppers-Lalic; Iris J C Dautzenberg; Oscar M J A Stassen; Montserrat Bárcena; Masato Yamamoto; Corrina M A de Ridder; Robert Kraaij; Kitty M Kwappenberg; Marco W Schilham; Rob C Hoeben
Journal:  Virology       Date:  2010-12-04       Impact factor: 3.616

5.  Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.

Authors:  Aleksei A Stepanenko; Anastasiia O Sosnovtseva; Marat P Valikhov; Anastasia A Chernysheva; Sergey A Cherepanov; Gaukhar M Yusubalieva; Zsolt Ruzsics; Anastasiia V Lipatova; Vladimir P Chekhonin
Journal:  Mol Ther Oncolytics       Date:  2021-12-21       Impact factor: 7.200

6.  Influence of cell physiological state on gene delivery to T lymphocytes by chimeric adenovirus Ad5F35.

Authors:  Wen-feng Zhang; Hong-wei Shao; Feng-lin Wu; Xin Xie; Zhu-ming Li; Hua-ben Bo; Han Shen; Teng Wang; Shu-lin Huang
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

7.  Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.

Authors:  Angelica Loskog; Tanja Lövgren; Jessica Wenthe; Sedigheh Naseri; Alireza Labani-Motlagh; Gunilla Enblad; Kristina I Wikström; Emma Eriksson
Journal:  Cancer Immunol Immunother       Date:  2021-03-05       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.